Merck CMV prophylaxis headed for U.S., EU submissions

Merck & Co. Inc. (NYSE:MRK) said it will submit applications in the U.S. and EU this year for letermovir (MK-8228) to prevent cytomegalovirus (CMV) infection in CMV-seropositive recipients

Read the full 285 word article

How to gain access

Continue reading with a
two-week free trial.